Moleculin Biotech CS (MBRX)

$3.90 -0.25 (-6.02%)
Market Cap 8.45M
Revenue (ttm) 0.00
Net Income (ttm) -21.76M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 126,000
Avg Vol 349,456
Day's Range N/A - N/A
Shares Out 2.04M
Stochastic %K 17%
Beta 1.58
Analysts Strong Sell
Price Target $26.50

Company Profile

Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to...

Industry: Biotechnology
Sector: Healthcare
Phone: 713 300 5160
Address:
5300 Memorial Drive, Suite 950, Houston, United States
SignalProcessor
SignalProcessor Dec. 25 at 3:07 PM
$MBRX This ticker is entering a stage where execution quality will overshadow headline narratives. Management alignment and prioritization play a larger role from here. Evidence of resilience during turbulence would be constructive. Over time, credibility will hinge on repeatable performance.
0 · Reply
Healthpro
Healthpro Dec. 24 at 7:18 PM
$MBRX reminds me of someone. Pathetic loser
0 · Reply
blueski12
blueski12 Dec. 24 at 5:18 PM
$MBRX i will buy under $1.X
0 · Reply
Healthpro
Healthpro Dec. 24 at 4:38 PM
$MBRX starts to rise back up in the past couple days then they wanna knock it down again.
0 · Reply
Healthpro
Healthpro Dec. 24 at 4:28 PM
$MBRX ATMs probably thanks to leadership.
0 · Reply
gianpinco
gianpinco Dec. 24 at 4:18 PM
$MBRX criminals
0 · Reply
mokaz1
mokaz1 Dec. 24 at 6:39 AM
$MBRX 좆 병신 고아기업 그냥 상폐나 처해라
0 · Reply
Healthpro
Healthpro Dec. 23 at 10:46 PM
$MBRX i’m sure a lot of bag holders are wishing they sold years ago. Imagine how much bonuses leadership took in the past 10 years and added it all up. Assuming 10 years times $1 million in bonus as a year equals $10 million. Why leadership taking bonuses in addition to their paychecks is beyond me.  All these analyst predictions are all downgraded compared to one month ago pre-reverse split. Do your due diligence.
0 · Reply
joedoe007
joedoe007 Dec. 23 at 7:07 PM
$MBRX If there is ever a buyout by big pharma or biotech, how much wud the big giants pay for MBRX , i mean 4 all of it ?? $15 ? $20 ??
0 · Reply
ezMoney001
ezMoney001 Dec. 23 at 6:49 PM
$MBRX One thing remains constant with this name..... NO NEWS IS GOOD NEWS !!!!
0 · Reply
Latest News on MBRX
Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Dec 17, 2025, 8:31 AM EST - 8 days ago

Moleculin Announces Positive Results from Phase 1 Clinical Trial Evaluating WP1066 for the Treatment of Pediatric Recurrent Malignant Brain Tumors

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Dec 10, 2025, 8:30 AM EST - 15 days ago

Moleculin Announces Exercise of Warrants for $6.8 Million Gross Proceeds

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Dec 9, 2025, 8:07 AM EST - 16 days ago

Moleculin Announces Completion of Treatment for the 45 Patients in Pivotal “MIRACLE” Phase 3 AML Trial on Pace for Q1 2026

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Dec 8, 2025, 8:21 AM EST - 17 days ago

Moleculin Announces New Annamycin Collaboration in Brain Tumors

Moleculin to Participate in the Virtual Investor Closing Bell Series

Nov 26, 2025, 9:15 AM EST - 4 weeks ago

Moleculin to Participate in the Virtual Investor Closing Bell Series

Moleculin Announces Reverse Stock Split

Nov 26, 2025, 9:00 AM EST - 4 weeks ago

Moleculin Announces Reverse Stock Split

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Nov 13, 2025, 8:36 AM EST - 6 weeks ago

Moleculin Reports 60% of First 45 Subjects in Pivotal “MIRACLE” Phase 3 AML Trial Consented

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Nov 12, 2025, 8:37 AM EST - 6 weeks ago

Moleculin Announces Grant Funded Research Evaluating Annamycin for the Treatment of Pancreatic Cancer at UNC-Chapel Hill

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Oct 30, 2025, 8:40 AM EDT - 2 months ago

Moleculin to Highlight its Ongoing Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial at the 14th Annual Acute Leukemia Meeting

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Oct 29, 2025, 8:35 AM EDT - 2 months ago

Moleculin Expands Global IP Portfolio with New Australian Patent for Annamycin

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Oct 23, 2025, 8:00 AM EDT - 2 months ago

Moleculin Announces New Investigator-Initiated Study of Annamycin for Treating Pancreatic Cancer

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Sep 25, 2025, 8:35 AM EDT - 3 months ago

Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Sep 9, 2025, 8:45 AM EDT - 3 months ago

Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Sep 8, 2025, 8:30 AM EDT - 3 months ago

Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Aug 28, 2025, 8:30 AM EDT - 4 months ago

Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds

Moleculin Issues New Positive AML Overall Survival Data:

Aug 27, 2025, 8:45 AM EDT - 4 months ago

Moleculin Issues New Positive AML Overall Survival Data:

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Aug 14, 2025, 9:15 AM EDT - 4 months ago

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Aug 13, 2025, 8:05 AM EDT - 4 months ago

Moleculin Reports Second Quarter 2025 Financial Results and Highlights

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Aug 6, 2025, 8:40 AM EDT - 5 months ago

Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Jul 30, 2025, 8:35 AM EDT - 5 months ago

Moleculin Receives Notice of Intent to Grant New European Patent for Annamycin

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 22, 2025, 8:45 AM EDT - 5 months ago

Moleculin Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Jul 17, 2025, 8:25 AM EDT - 5 months ago

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Jul 9, 2025, 8:35 AM EDT - 6 months ago

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans

Moleculin Announces $5.9 Million Public Offering

Jun 20, 2025, 9:20 AM EDT - 6 months ago

Moleculin Announces $5.9 Million Public Offering

Moleculin Participates in Virtual Investor “What This Means” Segment

Jun 18, 2025, 7:45 AM EDT - 6 months ago

Moleculin Participates in Virtual Investor “What This Means” Segment

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Jun 18, 2025, 7:30 AM EDT - 6 months ago

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Jun 5, 2025, 8:00 AM EDT - 7 months ago

Moleculin Releases On-Demand KOL Webcast to Discuss Data from its Phase 1B/2 Study of Annamycin for the Treatment of Soft Tissue Sarcoma (STS) Lung Metastases (MB-107)

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Jun 4, 2025, 8:45 AM EDT - 7 months ago

Moleculin Reports Positive Topline Efficacy Results from U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB-107)

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

May 14, 2025, 12:20 PM EDT - 8 months ago

Moleculin Biotech, Inc. (MBRX) Q1 2025 Earnings Call Transcript

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 14, 2025, 7:30 AM EDT - 8 months ago

Moleculin Reports First Quarter 2025 Financial Results and Provides Corporate Update

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

May 12, 2025, 8:40 AM EDT - 8 months ago

Moleculin Receives European Medicines Agency Approval to Expand Phase 3 MIRACLE Clinical Trial

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

May 7, 2025, 9:00 AM EDT - 8 months ago

Moleculin to Report First Quarter 2025 Financial Results on May 13, 2025 and Host Conference Call and Webcast

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

May 6, 2025, 9:00 AM EDT - 8 months ago

Moleculin Announces World Health Organization Approval of “naxtarubicin” as International Non-Proprietary Name for Annamycin

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

May 5, 2025, 8:45 AM EDT - 8 months ago

Moleculin Bolsters Annamycin Intellectual Property Portfolio with Granting of Two New U.S. Patents

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Apr 29, 2025, 8:35 AM EDT - 8 months ago

Moleculin Announces New Pre-Clinical Data for Annamycin Demonstrating Market Expansion Potential Including Treatment for Pancreatic Cancer

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Apr 17, 2025, 8:30 AM EDT - 9 months ago

Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2025

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Apr 1, 2025, 8:30 AM EDT - 9 months ago

Moleculin Doses First Patient in Pivotal, Adaptive Phase 3 MIRACLE Trial

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Mar 24, 2025, 10:50 AM EDT - 9 months ago

Moleculin Biotech, Inc. (MBRX) Q4 2024 Earnings Call Transcript

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 24, 2025, 7:05 AM EDT - 9 months ago

Moleculin Reports Full Year 2024 Financial Results and Provides Corporate Update

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Mar 19, 2025, 8:05 AM EDT - 10 months ago

Moleculin to Report Full Year 2024 Financial Results on March 21, 2025 and Host Conference Call and Webcast

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Mar 11, 2025, 8:45 AM EDT - 10 months ago

Moleculin Biotech, Inc. Participates in the Virtual Investor "Top 5 for '25" On-Demand Conference

Moleculin to Present at the 37th Annual ROTH Conference

Mar 10, 2025, 8:45 AM EDT - 10 months ago

Moleculin to Present at the 37th Annual ROTH Conference

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Mar 6, 2025, 8:30 AM EST - 10 months ago

Moleculin Announces Additional Annamycin Patent Allowances to Enhance Global Exclusivity

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Mar 3, 2025, 8:30 AM EST - 10 months ago

Moleculin Abstract Accepted for Poster Presentation at the Acute Leukemias XIX (ISALXIX) International Symposium

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Feb 25, 2025, 12:35 PM EST - 10 months ago

Moleculin Announces Pricing of $3.5 Million Registered Direct Offering and Concurrent Private Placement Priced At The Market Under Nasdaq Rules

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Feb 13, 2025, 1:19 PM EST - 11 months ago

Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Feb 13, 2025, 1:05 PM EST - 11 months ago

Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Feb 13, 2025, 9:25 AM EST - 11 months ago

Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Feb 11, 2025, 8:40 AM EST - 11 months ago

Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial

Moleculin Participates in Virtual Investor "What This Means" Segment

Jan 27, 2025, 8:30 AM EST - 11 months ago

Moleculin Participates in Virtual Investor "What This Means" Segment

SignalProcessor
SignalProcessor Dec. 25 at 3:07 PM
$MBRX This ticker is entering a stage where execution quality will overshadow headline narratives. Management alignment and prioritization play a larger role from here. Evidence of resilience during turbulence would be constructive. Over time, credibility will hinge on repeatable performance.
0 · Reply
Healthpro
Healthpro Dec. 24 at 7:18 PM
$MBRX reminds me of someone. Pathetic loser
0 · Reply
blueski12
blueski12 Dec. 24 at 5:18 PM
$MBRX i will buy under $1.X
0 · Reply
Healthpro
Healthpro Dec. 24 at 4:38 PM
$MBRX starts to rise back up in the past couple days then they wanna knock it down again.
0 · Reply
Healthpro
Healthpro Dec. 24 at 4:28 PM
$MBRX ATMs probably thanks to leadership.
0 · Reply
gianpinco
gianpinco Dec. 24 at 4:18 PM
$MBRX criminals
0 · Reply
mokaz1
mokaz1 Dec. 24 at 6:39 AM
$MBRX 좆 병신 고아기업 그냥 상폐나 처해라
0 · Reply
Healthpro
Healthpro Dec. 23 at 10:46 PM
$MBRX i’m sure a lot of bag holders are wishing they sold years ago. Imagine how much bonuses leadership took in the past 10 years and added it all up. Assuming 10 years times $1 million in bonus as a year equals $10 million. Why leadership taking bonuses in addition to their paychecks is beyond me.  All these analyst predictions are all downgraded compared to one month ago pre-reverse split. Do your due diligence.
0 · Reply
joedoe007
joedoe007 Dec. 23 at 7:07 PM
$MBRX If there is ever a buyout by big pharma or biotech, how much wud the big giants pay for MBRX , i mean 4 all of it ?? $15 ? $20 ??
0 · Reply
ezMoney001
ezMoney001 Dec. 23 at 6:49 PM
$MBRX One thing remains constant with this name..... NO NEWS IS GOOD NEWS !!!!
0 · Reply
IVALTE
IVALTE Dec. 23 at 6:42 PM
$MBRX next $DRUG
0 · Reply
joedoe007
joedoe007 Dec. 23 at 6:41 PM
$MBRX Any chance of a BUYOUT scenario where a big biotech or pharma outfit just scoops up Moleculin while its still cheapies and in the dirt???
0 · Reply
GTMStox
GTMStox Dec. 23 at 6:25 PM
$MBRX These crooks continue to lower the price on warrants. They love diluting and screwing over shareholders.
0 · Reply
Healthpro
Healthpro Dec. 23 at 4:22 PM
$MBRX take all these analyst predictions now multiplied by 25  adjusting for pre-reverse split. All of them show a significant downgrade on their pricing. Don’t let perfect storm confuse anyone. This is a joke and I can’t wait until SEC investigates what’s going on
0 · Reply
merlin8121
merlin8121 Dec. 23 at 3:52 PM
$MBRX https://www.merlintrader.com/mbrx-mileculin-biotech/
0 · Reply
Stormra
Stormra Dec. 23 at 2:47 PM
$MBRX
0 · Reply
Stormra
Stormra Dec. 23 at 2:46 PM
$MBRX
0 · Reply
Zemmy163walla
Zemmy163walla Dec. 23 at 1:01 PM
$FJET $SIDU $MBRX $CETX
0 · Reply
aj_hollins
aj_hollins Dec. 22 at 5:23 PM
$MBRX this ain't over yet.
0 · Reply
Fnkychld
Fnkychld Dec. 21 at 8:44 AM
$MBRX no tricks.
0 · Reply
KaydenG1
KaydenG1 Dec. 19 at 3:18 PM
$MBRX thoughts of it going back to 4?
0 · Reply
Stormra
Stormra Dec. 19 at 2:32 PM
$MBRX WHAT????
0 · Reply